Furthermore, it has been demonstrated that melanomas develop resistance to these inhibitors due to secondary mutations in V-Ras neuroblastoma RAS viral oncogene homolog (NRAS) and other mutational alterations [17,18]. The gene discussed is NRAS; the disease is melanoma.